Connect your AI

Evolus EOLS Cumulative Cost Basis

Cumulative Cost Basis at other companies

AbbVieABBV

——

Other financials

Income statement

Revenue$73.1M+6.7%

Gross profit$48.9M+4.8%

Operating income-$6.8M+54.9%

Net income-$10.7M+43.5%

EPS (diluted)-$0.16+46.7%

Balance sheet

Cash & equivalents$49.8M-26.7%

Total debt$164.9M-4.1%

Total equity-$28.8M-336%

Total assets$220.6M+3.4%

Cash flow

Operating cash flow-$10.0M+36.3%

CapEx$415.0K+30.1%

Free cash flow-$10.4M+35.0%

Valuation

Market cap$470.86M-21.3%

Enterprise value$585.97M-16.6%

P/S1.6×-0.6×

Profitability

Gross margin66.1%-2.4pp

Operating margin-13.7%-1.9pp

Net margin-14.4%-3.3pp

FCF margin-9.6%-3.6pp

Returns & leverage

Return on equity-472.6%-1,534pp

Debt / equity22.2×—

Current ratio2×-0.3×

Where this comes from

Reported directly by Evolus in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentGross.

The official record: Evolus’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evolus's cumulative cost basis.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Evolus's cumulative cost basis?: Evolus (EOLS) reported cumulative cost basis of $10.54M in Q1 2026.
How has Evolus's cumulative cost basis changed year-over-year?: Evolus's cumulative cost basis increased by 49.2% year-over-year, from $7.07M to $10.54M.